

Sonoma Pharmaceuticals reported record Q1 revenue, narrow loss, doubled U.S. sales and achieved positive adjusted EBITDA for the first time.
You can purchase shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) through any online brokerage.
Other companies in Sonoma Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
There is no analysis for Sonoma Pharmaceuticals to provide a consensus price target.
The stock price for Sonoma Pharmaceuticals (NASDAQ: SNOA) is $1.14 last updated October 28, 2026 at 1:41 PM EDT.
There are no upcoming dividends for Sonoma Pharmaceuticals.
Sonoma Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Sonoma Pharmaceuticals.
Sonoma Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company...